Viviora Lifesciences Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Viviora Lifesciences Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $77.1K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Viviora Lifesciences Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $77.1K Trade | TransData Nexus

Viviora Lifesciences Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $77.1K Total Trade · DGFT Verified

Viviora Lifesciences Private Limited is an Indian pharmaceutical exporter with a total trade value of $77.1K across 2 products in 2 therapeutic categories. Based on 7 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ifosfamide ($53.9K), Vinblastine ($23.2K), .

Viviora Lifesciences Private Limited — Export Portfolio & Destination Treemap

Viviora Lifesciences Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Viviora Lifesciences Private Limited? — Company Overview & Market Position

Viviora Lifesciences Private Limited, established on December 6, 2017, is a private pharmaceutical company headquartered in Pune, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U74999PN2017PTC173716. Its authorized and paid-up capital are both ₹100,000. The registered office is located at Plot No 12, Sr No 253/2/2, Tirumala Industrial Estate, Road Rajiv Gandhi IT Park Phase 2, Hinjawadi, Pune, Maharashtra, 411057.

Viviora Lifesciences specializes in the formulation and development of pharmaceutical products, focusing on finished pharmaceutical formulations such as tablets, capsules, syrups, and injections. The company's portfolio includes a diverse range of oral dosage forms, including tablets, capsules, syrups, sachets, injectables, specialized products for cancer treatment, critical care items, and topical preparations.

As of the latest available data, Viviora Lifesciences has reported a total export value of $77,000 USD across seven shipments, exporting two products across two therapeutic categories. The top five products include Ifosfamide ($54,000, Rank #8, 2.2% market share) and Vinblastine ($23,000, Rank #8, 3.1% market share). The primary therapeutic categories are Advanced Oncology (69.8%) and Oncology (30.2%). The company's portfolio is highly concentrated, with the top five products accounting for 100% of its exports.

What Does Viviora Lifesciences Private Limited Export? — Product Portfolio Analysis

Product Portfolio — Top 2 by Export Value

Viviora Lifesciences Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ifosfamide	Advanced Oncology	$53.9K	4	2.2%	8
2	Vinblastine	Oncology	$23.2K	3	3.1%	8

Viviora Lifesciences Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $77.1K. The top category is Advanced Oncology (69.8% of portfolio), followed by Oncology (30.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Viviora Lifesciences Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Viviora Lifesciences operates manufacturing facilities in Pune, Maharashtra, India. The company's registered office is located at Plot No 12, Sr No 253/2/2, Tirumala Industrial Estate, Road Rajiv Gandhi IT Park Phase 2, Hinjawadi, Pune, Maharashtra, 411057. Specific details regarding the capacities and specializations of these facilities are not publicly disclosed.

3Key Leadership

The company's leadership comprises two directors:

Revanasiddayya: Director since December 6, 2017.

Pallavi: Director since December 6, 2017.

Both directors have been associated with Viviora Lifesciences since its inception.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Viviora Lifesciences Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Viviora Lifesciences has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained various regulatory approvals and certifications, such as WHO-GMP, EU-GMP, and MHRA-UK, facilitating market access in these regions.

2Emerging Markets

Viviora Lifesciences has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's products are registered with regulatory authorities in countries like Ethiopia, Ghana, Kenya, Nigeria, and the Philippines, enabling access to these markets.

3Geographic Strategy

Viviora Lifesciences demonstrates a diversified geographic strategy by exporting to over 30 countries across various continents. This approach mitigates concentration risk and aligns with the company's mission to provide accessible and sustainable healthcare solutions globally.

Viviora Lifesciences Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Viviora Lifesciences' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company holds WHO-GMP certification, which may facilitate market access in the United States.

2WHO & EU GMP

Viviora Lifesciences has obtained WHO-GMP and EU-GMP certifications, indicating compliance with international manufacturing standards. These certifications enhance the company's credibility and facilitate market access in regions requiring such compliance.

3CDSCO & Indian Regulatory

Viviora Lifesciences holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained approvals from state drug controllers. The company has also secured export No Objection Certificates (NOCs), enabling the export of its products to various international markets.

Viviora Lifesciences Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Viviora Lifesciences operates in the competitive pharmaceutical export market, focusing on oncology products. While specific competitors are not identified, the company's emphasis on specialized oncology treatments positions it within a niche segment, potentially reducing direct competition.

2Key Differentiators

Viviora Lifesciences' key differentiators include its specialized product portfolio in oncology and critical care, adherence to international manufacturing standards, and a diversified geographic presence. These factors contribute to the company's competitive advantage in the global pharmaceutical market.

3Strategic Position

Viviora Lifesciences is strategically positioned as a manufacturer and exporter of specialized pharmaceutical products, particularly in oncology and critical care. The company's future outlook includes expanding its product offerings and enhancing its presence in emerging markets to achieve sustainable growth.

Buyer Due Diligence Brief — Evaluating Viviora Lifesciences Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Viviora Lifesciences demonstrates a strong track record in pharmaceutical manufacturing, with a focus on oncology and critical care products. The company's export volume and consistency are supported by its adherence to international manufacturing standards and certifications. Reliability indicators include its compliant status with regulatory authorities and a diversified geographic presence.

2Certifications to Verify

Importers should verify the following certifications when considering Viviora Lifesciences as a supplier:

WHO-GMP: Verify through the World Health Organization's official website or contact Viviora Lifesciences directly.

EU-GMP: Check the European Medicines Agency's database or request certification details from the company.

MHRA-UK: Consult the UK's Medicines and Healthcare products Regulatory Agency for certification status.

Frequently Asked Questions — Viviora Lifesciences Private Limited

How many pharmaceutical products does Viviora Lifesciences Private Limited export from India?

Viviora Lifesciences Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Ifosfamide ($53.9K), Vinblastine ($23.2K). Total export value is $77.1K.

What is Viviora Lifesciences Private Limited's total pharmaceutical export value?

Viviora Lifesciences Private Limited's total pharmaceutical export value is $77.1K, based on 7 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Viviora Lifesciences Private Limited cover?

Viviora Lifesciences Private Limited exports across 2 therapeutic categories. The largest are Advanced Oncology (69.8%, 1 products), Oncology (30.2%, 1 products).

Get Full Viviora Lifesciences Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.